| ￥3000 | |
| Z05456-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 39.3 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized IL-18RAP/IL-18 R beta, His, Human, His Tag at 1μg/ml(100 μl/well) on the plate. Dose response curve for Anti-IL-18RAP Antibody, hFc Tag with the EC50 of 4.8 ng/ml determined by ELISA. »
The purity of IL-18RAP/IL-18 R beta, His, Human is greater than 95% as determined by SEC-HPLC. »
IL-18RAP/IL-18 R beta, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | lactoferrin (LTF), peptidoglycan recognition protein 1 and IL-18 receptor accessory protein (IL-18RAP) remained significantly elevated in peripheral monocytes of hypertensive individuals in a separate validation cohort. Interestingly, IL18RAP expression associated with MAP in a cohort of African Americans.. |
| Synonyms | IL-18 R beta; ACPL; CD218b; CDw218b; IL-18R-beta; IL-18RAcP; IL-18Rbeta; IL-1R-7; IL-1R7; IL-1RAcPL; IL18RB; IL18RAP; IL-18R-beta; IL-18R-β; IL-18Rβ |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
